Category: Knowledge Base

If you are taking tirzepatide for weight loss and wondering whether you can still have a glass of wine at dinner or a beer at a weekend barbecue, you are far from alone. This is one of the most common questions patients ask their providers, and it deserves a straightforward, practical answer.

Here is the bottom line: alcohol is not contraindicated with tirzepatide per the FDA labeling. There is no listed drug interaction that says you absolutely cannot drink. 

But there are several practical reasons to be cautious, and understanding those reasons will help you make informed decisions rather than simply following a blanket rule.

This article is for general informational purposes. Talk to your provider about how alcohol use fits within your individual treatment plan.

What Actually Happens When You Drink on Tirzepatide

To understand why alcohol and tirzepatide can be a tricky combination, it helps to know what tirzepatide does to your digestive system.

Tirzepatide is a dual GLP-1/GIP receptor agonist. One of its primary mechanisms is slowing gastric emptying, meaning food stays in your stomach longer than it otherwise would. That is part of how the medication reduces appetite and helps you feel satisfied with smaller portions.

When you add alcohol into a stomach that is already emptying slowly, a few things can happen. Alcohol may be absorbed differently than you are used to. Some patients report feeling the effects of a single drink much more quickly, or feeling more intoxicated than they would expect from the same amount of alcohol they used to tolerate. 

A study published in Scientific Reports found that participants taking GLP-1 and GLP-1/GIP agonists reported reduced sedative and stimulating effects of alcohol, alongside changes in overall drinking behavior. The altered absorption pattern from delayed gastric emptying likely plays a role.

Nausea can also become a bigger problem. If you are already experiencing GI side effects from tirzepatide, and many patients do, especially during dose escalation, alcohol can amplify them. Even a moderate amount of alcohol can irritate the stomach lining and worsen nausea that would otherwise be manageable.

The Calorie and Blood Sugar Factor

Beyond how alcohol makes you feel physically, there are two metabolic considerations worth thinking about.

First, alcohol carries calories that provide no nutritional value. A standard glass of wine contains roughly 120 to 150 calories. A pint of beer runs 150 to 200. Cocktails with mixers can easily exceed 300. 

When tirzepatide is working to create a caloric deficit and shift your metabolism toward fat loss, those empty calories can quietly undermine your progress. This is not about being rigid, but about being aware.

Second, alcohol affects blood sugar regulation. Tirzepatide already influences insulin secretion and glucose metabolism. Adding alcohol into that equation, especially on an empty stomach, can create unpredictable blood sugar swings. 

For patients who are also managing type 2 diabetes or prediabetes, this is a conversation you should definitely have with your provider before your next social event.

So, Can You Have a Drink?

Yes, most patients can have an occasional drink without causing harm. The goal is not prohibition. It is informed decision-making.

Here are some practical strategies that many patients find helpful. Eating before you drink is important, because drinking on an empty stomach when your gastric emptying is already slowed is a recipe for feeling unwell quickly. 

Starting with less than you normally would makes sense because your tolerance has likely changed. Staying hydrated by alternating water between drinks helps counter the dehydrating effects of both alcohol and tirzepatide. 

Avoiding sugary cocktails can prevent the blood sugar roller coaster that comes with high-sugar mixers. And paying attention to how you feel is the simplest and most effective strategy of all. If one drink makes you feel like you have had three, your body is telling you something.

It is also worth noting that some patients find their desire to drink decreases naturally while on tirzepatide. Early research suggests that GLP-1 medications may influence the brain’s reward pathways in ways that reduce alcohol cravings. If you notice you are less interested in drinking, that is not unusual.

Choosing Your Drinks Wisely

If you do decide to drink, some choices are easier on your body than others while on tirzepatide.

Light beers and dry wines tend to be better tolerated than heavy craft beers or sweet wines, both in terms of calorie content and GI comfort. Spirits mixed with soda water or served on the rocks are lower in sugar than cocktails made with juice, soda, or flavored syrups. 

Drinks like margaritas, pina coladas, and Long Island iced teas can pack 400 or more calories each, which adds up quickly when your treatment plan depends on a caloric deficit.

If wine is your preference, a single five-ounce pour is a reasonable starting point. If you prefer beer, a standard 12-ounce serving is enough to gauge how your body responds. The important thing is to start small, see how you feel, and adjust from there rather than matching your pre-tirzepatide drinking habits right out of the gate.

When to Be Extra Careful

There are specific situations where alcohol and tirzepatide do not mix well.

During dose escalation is one of them. The first few weeks at each new dose are when GI side effects tend to peak. 

Adding alcohol during this period is likely to make nausea, diarrhea, or stomach discomfort worse. If you know you have an event coming up where you will want to drink, timing your dose increase around it may be worth discussing with your provider.

Patients with a history of pancreatitis should be particularly cautious. Both GLP-1 agonists and heavy alcohol use are independently associated with pancreatic stress, and combining them may elevate that risk. This does not mean occasional moderate drinking is dangerous for everyone, but it does mean the conversation with your provider becomes more important.

If you are taking other medications alongside tirzepatide, particularly insulin or sulfonylureas for diabetes, alcohol’s effect on blood sugar becomes a more serious concern. Hypoglycemia (dangerously low blood sugar) can occur because alcohol interferes with the liver’s ability to release stored glucose.

What About Long-Term Weight Loss Goals?

Putting the immediate physical effects aside, it is worth thinking about how alcohol fits into your broader treatment picture.

Patients on tirzepatide weight loss programs are investing time, money, and effort into changing their body composition and metabolic health. Regular or heavy drinking can work against those goals in ways that go beyond calories. 

Alcohol disrupts sleep quality (even when it feels like it helps you fall asleep), lowers inhibitions around food choices, and interferes with the metabolic improvements the medication is trying to create.

None of that means you need to eliminate alcohol completely. It means that treating alcohol as an occasional indulgence rather than a regular habit will support your results.

For patients who want to maximize their outcomes, focusing on evidence-based nutrition strategies alongside their medication, including adequate protein intake and smart meal timing, will have a bigger impact on their results than worrying about the occasional drink.

Talk to Your Provider

The most important takeaway is that alcohol is not a simple yes-or-no question on tirzepatide. It depends on where you are in your dosing schedule, how your body is responding to the medication, what other medications you are taking, and what your individual health picture looks like.

Your telehealth provider is a great resource for lifestyle questions like this one. A quick check-in is all it takes to get personalized guidance about how alcohol fits into your specific treatment plan. It is a completely normal question, and your care team has heard it before.

This article is for general informational purposes. Talk to your provider about how alcohol use fits within your individual treatment plan.

If you have spent any time researching medical weight loss, you have probably run into this question. And you have probably found a dozen articles that each give a slightly different answer, usually leaning toward whichever medication the writer’s platform happens to sell.

Here is the honest answer up front: there is no single “best” GLP-1 for weight loss. The medication that works best is the one that fits your individual health profile, your tolerance for side effects, your budget, and your long-term goals. That is not a cop-out answer. It is the clinically accurate one.

What we can do is look at the evidence for the major GLP-1 options, compare what the trials actually show, and help you understand the factors that matter when making this decision with your provider.

Individual results vary. Drug selection should be based on a thorough medical evaluation with a licensed provider.

The GLP-1 Medications Currently Available

Three medications dominate the conversation around GLP-1 therapy for weight loss. Understanding what each one is and how it works will help frame the comparison.

Semaglutide is a GLP-1 receptor agonist, meaning it targets a single receptor system. It is the active ingredient in Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). Semaglutide is also available in compounded formulations through licensed pharmacies. It is administered as a once-weekly subcutaneous injection.

Tirzepatide is a dual GLP-1/GIP receptor agonist. It targets both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, which is why you will sometimes hear it described as a “dual agonist” or “twincretin.” Tirzepatide is the active ingredient in Mounjaro (for diabetes) and Zepbound (for weight management). It is also available as a compounded medication through qualified pharmacies. Like semaglutide, it is a weekly injection.

Liraglutide (brand name Saxenda) is an older GLP-1 receptor agonist that requires daily injections. While it was the first GLP-1 approved specifically for weight management, its clinical outcomes are more modest compared to semaglutide and tirzepatide. For that reason, liraglutide is prescribed less frequently for weight loss today, though it remains an option in specific clinical situations.

What the Clinical Trial Data Shows

Clinical trials give us the most objective comparison we have, though it is important to understand their limitations. Most of the major trials compared each drug against placebo, not directly against each other, which makes head-to-head conclusions tricky.

The STEP trial program evaluated semaglutide 2.4 mg for weight management. In the landmark STEP 1 trial published in the New England Journal of Medicine, participants without diabetes lost an average of approximately 15% of their body weight over 68 weeks. Around 86% of participants achieved at least 5% weight loss, and about a third lost 20% or more. Those numbers were considered remarkable at the time of publication.

The SURMOUNT trial program evaluated tirzepatide. In the SURMOUNT-1 trial, also published in the NEJM, the results were even more striking. Participants on the highest dose (15 mg) lost an average of 22.5% of their body weight over 72 weeks. Roughly 96% of participants on the 10 mg and 15 mg doses achieved at least 5% weight loss, and more than half on the highest dose lost over 20%.

On raw percentage weight loss, tirzepatide appears to have an edge. But there are a few things to consider before concluding that it is automatically “better.”

Why the Numbers Do Not Tell the Whole Story

Trial populations were not identical. The STEP and SURMOUNT participants had somewhat different demographic profiles, baseline BMIs, and comorbidity distributions. Comparing average outcomes across different trial populations is informative but not the same as a controlled head-to-head study.

Side effect profiles differ. Both medications cause gastrointestinal side effects, but the patterns are not identical. Some patients tolerate semaglutide well but struggle with tirzepatide, and the reverse is also true. Nausea, constipation, and diarrhea are common with both, particularly during dose escalation. Your personal tolerance can make or break your experience with either medication.

Cost and access vary. Brand-name tirzepatide and semaglutide have different pricing structures, insurance coverage patterns, and availability through compounding pharmacies. For some patients, the “best” medication is the one they can actually afford and access consistently.

Individual metabolic response is unpredictable. Some patients respond dramatically to semaglutide and see only modest additional benefit from tirzepatide. Others plateau on semaglutide and do significantly better after switching. There is currently no reliable way to predict which patient will respond best to which drug before trying it.

Factors That Actually Guide the Decision

When a provider is helping a patient choose between GLP-1 options, they consider a combination of clinical and practical factors. Here are the ones that matter most.

Health history and comorbidities play a role. Both medications carry an FDA boxed warning regarding thyroid C-cell tumors (based on rodent data), and both are contraindicated in patients with a history of medullary thyroid carcinoma or MEN2. 

Beyond that, factors like existing diabetes, cardiovascular risk, kidney function, and history of pancreatitis can all influence which drug is a better fit. You can review the full scope of prescribing and safety considerations to understand what providers evaluate.

Side effect tolerance is practical and personal. If a patient has had significant GI issues on one medication, switching to the other is a reasonable clinical move. Some patients find that tirzepatide’s dual mechanism produces a different side effect experience than semaglutide’s GLP-1 monoagonism.

Cost and insurance coverage often end up being the deciding factor for many patients. Brand-name Wegovy and Zepbound are expensive, and insurance coverage is inconsistent. Compounded options through programs like those offered by Precision Telemed can make both medications significantly more accessible, but patients should understand what they are getting and from where.

Patient preference and lifestyle fit matter too. Some patients prefer the idea of a dual-agonist mechanism. Others want to start with the medication that has the longer track record (semaglutide has been on the market longer than tirzepatide for weight management). Neither preference is wrong.

What About Maintenance and Long-Term Use?

Weight loss medications are not short-term interventions. The clinical data consistently shows that weight tends to return when treatment is discontinued. This means the choice of medication is also a question about long-term tolerability and sustainability.

For patients who have reached their goal weight and want to transition to a lower maintenance dose, both semaglutide and tirzepatide offer options. Some providers use microdose GLP-1 protocols for long-term maintenance, keeping patients on a lower dose to sustain results without the full side effect burden of a therapeutic dose.

The “best” GLP-1 for maintenance may not be the same as the best one for initial weight loss. Some patients achieve their target on tirzepatide and then transition to semaglutide for maintenance. Others stay on the same medication at a reduced dose. This is another decision that benefits from ongoing provider guidance.

So, Which One Should You Choose?

If you were hoping for a definitive answer, I understand the frustration. But the truth is that drug selection should be based on a thorough medical evaluation, not on an internet article telling you which one “wins.” 

Both semaglutide and tirzepatide are highly effective GLP-1 medications with strong clinical data behind them. The one that is best for you depends on your health history, your goals, your tolerance, and your circumstances.

The most productive next step is to have that conversation with a provider who can review your complete picture. A telehealth consultation is built for exactly this kind of decision. Your provider can walk through both options with you, explain how each one might work for your specific situation, and help you make an informed choice based on real clinical criteria, not marketing.

Individual results vary. Drug selection should be based on a thorough medical evaluation with a licensed provider.

This is a question that providers genuinely hear on a regular basis, and it deserves a thorough, honest answer. 

As more patients explore medical weight loss alongside peptide therapies for energy, recovery, and body composition, the idea of combining semaglutide with sermorelin naturally comes up. It makes intuitive sense: one helps with fat loss, the other supports muscle preservation. But intuition and pharmacology are not always the same thing, so let’s look at what the science actually says.

The short answer is that semaglutide and sermorelin work through entirely different biological pathways, and there is no known direct pharmacological conflict between them. That said, whether combining them is appropriate for you depends on your individual health history, and that decision belongs to your provider.

This article is for informational purposes only and does not constitute medical advice. Whether these medications are appropriate together depends on your individual health history and should only be decided with a licensed provider.

How Semaglutide Works

Semaglutide is a GLP-1 receptor agonist, meaning it mimics a hormone called glucagon-like peptide-1 that your body naturally produces after eating. GLP-1 does several things at once: it signals your brain to feel full, slows down how quickly food leaves your stomach, and helps regulate insulin secretion. The net effect for most patients is a significant reduction in appetite and caloric intake, which leads to progressive weight loss over time.

The clinical data behind semaglutide is substantial. The STEP trial program, published across multiple peer-reviewed journals including the New England Journal of Medicine, demonstrated average weight loss of approximately 15% of body weight over 68 weeks in participants without diabetes. These are the kinds of results that have made semaglutide programs one of the most in-demand treatments in telehealth.

Semaglutide is administered as a once-weekly subcutaneous injection and follows a titration schedule, starting low and gradually increasing to a therapeutic dose.

How Sermorelin Works

Sermorelin operates on a completely different system. It is a synthetic analog of growth hormone-releasing hormone (GHRH), the 29-amino-acid fragment that retains the full biological activity of the naturally occurring hormone. 

Rather than introducing growth hormone directly into the body, sermorelin stimulates the pituitary gland to produce and release its own growth hormone in a pulsatile, physiologically normal pattern.

A review published in Clinical Interventions in Aging outlines several advantages of this approach over direct growth hormone injections. Because sermorelin works through the body’s existing feedback mechanisms, including the inhibitory effects of somatostatin, the risk of pushing growth hormone levels above physiological norms is low. The pituitary gland essentially self-regulates the response.

Growth hormone plays a well-documented role in body composition: it supports lean muscle maintenance, promotes fat metabolism, and contributes to tissue repair and recovery. These are the reasons patients on sermorelin therapy programs often report improvements in sleep quality, energy levels, and body composition over a period of several months.

Sermorelin is also administered as a subcutaneous injection, though it is typically given daily, most often at bedtime to align with the body’s natural nocturnal growth hormone release cycle.

Why the Combination Makes Pharmacological Sense

Here is the clinical rationale that providers consider. Semaglutide and sermorelin act on entirely separate receptor systems. Semaglutide targets GLP-1 receptors in the brain and gut. Sermorelin targets GHRH receptors on the pituitary gland. They do not compete for the same receptors, they do not share metabolic pathways, and they do not produce overlapping mechanisms that would create a direct conflict.

The practical appeal of combining them comes down to body composition. One of the known challenges with rapid weight loss from any cause is the potential loss of lean muscle mass alongside fat. This is not unique to GLP-1 medications; it happens with caloric restriction, bariatric surgery, and most other approaches to significant weight loss. Maintaining adequate protein intake and incorporating resistance training helps, but some providers also consider growth hormone optimization as an additional strategy.

By supporting the body’s natural growth hormone production, sermorelin may help preserve lean tissue during the weight loss process. Meanwhile, semaglutide drives the caloric deficit through appetite reduction. In theory, the two medications target complementary aspects of body composition.

The Important Caveats

All of that said, there are real considerations that patients should not overlook.

First, large-scale clinical trials specifically testing the combination of semaglutide and sermorelin together do not currently exist. The rationale for combining them is based on their individual mechanisms and the absence of known interactions, not on a dedicated combination trial. That is an honest distinction worth making.

Second, both medications are prescription drugs that require independent clinical assessment. Being a good candidate for semaglutide does not automatically mean you are a candidate for sermorelin, or vice versa. Each medication has its own set of contraindications. 

For example, sermorelin is generally not appropriate for patients with active malignancies because growth hormone stimulation could theoretically promote tumor growth. Your provider needs to evaluate both medications in the context of your complete health profile.

Third, combining two injectable medications means managing two separate protocols with different dosing schedules, injection timing, and monitoring requirements. This is entirely doable, but it does require organization and consistent follow-up with your care team.

Fourth, cost is a practical factor. Running both therapies simultaneously means paying for two medications each month. Some patients find the investment worthwhile for the body composition benefits; others prefer to focus on one medication at a time.

What Providers Actually Consider Before Prescribing Both

When a patient asks about combining semaglutide and sermorelin, a responsible provider will look at several factors. 

They will review baseline lab work, including IGF-1 levels (a marker for growth hormone status), thyroid function, and metabolic markers. They will assess whether the patient has documented growth hormone insufficiency or age-related decline that would make sermorelin clinically justified. 

They will also consider the patient’s current response to semaglutide and whether adding sermorelin addresses a specific concern like muscle loss, fatigue, or poor recovery.

Good providers do not prescribe both medications to every patient by default. They prescribe sermorelin when the clinical picture supports it and when the potential benefit outweighs the added complexity and cost of a dual protocol.

Patients who are already on a weight loss program and are concerned about lean mass may want to discuss their labs and body composition goals with their provider before adding a second medication. Sometimes dietary adjustments and exercise modifications are enough. Sometimes sermorelin adds something meaningful. That conversation is exactly what your provider is there for.

The Bottom Line

Semaglutide and sermorelin work through entirely different biological systems, and there is no known direct pharmacological conflict between them. Many providers consider the combination clinically reasonable for patients who want to optimize body composition during weight loss. But “clinically reasonable” is not the same as “right for everyone,” and the combination should only be managed by a licensed prescribing provider who has reviewed your full health history.

If you are curious about whether combining both therapies could make sense for your situation, scheduling a telehealth consultation is the most efficient way to get a personalized answer. Your provider can review your labs, discuss your goals, and determine whether a combination protocol is appropriate for you specifically.

This article is for informational purposes only and does not constitute medical advice. Whether these medications are appropriate together depends on your individual health history and should only be decided with a licensed provider.

Compounded tirzepatide has become one of the most searched weight loss topics online, and for good reason. Tirzepatide is a dual GLP-1/GIP receptor agonist that produced some of the most impressive weight loss results ever seen in clinical trials. 

In the SURMOUNT-1 study, participants on the highest dose lost an average of over 22% of their body weight over 72 weeks. Those are numbers that were once only achievable through bariatric surgery.

But the pathway to getting compounded tirzepatide is not as simple as it used to be, and there is a lot of outdated or misleading information floating around. 

The regulatory picture has shifted significantly since 2024, and patients considering this option need to understand what has changed, what is still legal, and how to do it safely.

This article walks through the current state of compounded tirzepatide, who it may be appropriate for, and how the prescription process works through a telehealth provider.

What Is Compounded Tirzepatide, Exactly?

Let’s start with the basics. Brand-name tirzepatide is sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight management), both manufactured by Eli Lilly. These are FDA-approved products.

Compounded tirzepatide is a version of the same active ingredient, prepared by a licensed compounding pharmacy rather than the brand-name manufacturer. Compounding pharmacies produce medications tailored to individual patient needs, and they operate under FDA oversight through either Section 503A (state-licensed pharmacies) or Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act.

Here is the important distinction that many articles skip over: compounded versions are produced in FDA-registered facilities, but they are not FDA-approved as brand-name drugs. The active ingredient is the same, but the final product has not gone through the same approval process as Mounjaro or Zepbound. This matters, and any provider or website that glosses over this difference is not giving you the full picture.

The Regulatory Reality in 2025 and Beyond

This is where things get complicated, and where most online content falls short.

During 2022 through 2024, tirzepatide was on the FDA’s drug shortage list, which created a temporary window during which compounding pharmacies were permitted to produce copies of the drug to help meet patient demand. That shortage designation was resolved in October 2024, and the FDA subsequently issued enforcement timelines for compounders to wind down production.

Section 503B outsourcing facilities were required to stop compounding tirzepatide by March 2025. Section 503A state-licensed pharmacies had an earlier deadline, though ongoing litigation between the Outsourcing Facilities Association and the FDA has created some complexity around enforcement timelines.

So where does that leave patients today? Section 503A pharmacies can still legally compound tirzepatide for individual patients when a licensed provider writes a prescription with documented clinical justification. The key word there is “individual.” Bulk production and mass distribution are no longer permitted the way they were during the shortage. 

A compounded version must represent a meaningful modification from the commercially available product, or the patient must have a documented clinical need that the brand-name product cannot meet.

The availability and legal status of compounded tirzepatide is subject to FDA regulation and may change. This article reflects information available at the time of publication. Always consult a licensed provider.

Who Is a Candidate for Compounded Tirzepatide?

Not everyone who wants tirzepatide will be prescribed it, and that is how it should be. This is a medication with real physiological effects that requires proper medical evaluation.

Generally, tirzepatide may be appropriate for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Your provider will evaluate your full medical history during your consultation.

There are also important contraindications. Tirzepatide carries an FDA boxed warning regarding thyroid C-cell tumors observed in rodent studies. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not use this medication. Your provider should ask about this directly, and if they don’t, bring it up yourself.

For patients who are exploring their options between different GLP-1 medications, it may also help to understand how compounded semaglutide works as an alternative pathway. Some patients do better on one medication than the other based on side effect tolerance, cost, and individual response.

How the Telehealth Prescription Process Works

If you have decided you want to explore compounded tirzepatide, working with a telehealth provider is one of the most straightforward paths. Here is how it typically unfolds.

You begin with an online intake form. This covers your medical history, current medications, weight and height, previous weight loss attempts, and any relevant conditions. Be honest and thorough. The provider is using this information to make a clinical decision about your safety, not to judge you.

Next comes the provider consultation. A licensed healthcare professional reviews your intake and meets with you, either asynchronously (reviewing your submitted information and responding) or through a live telehealth visit. 

During this step, the provider determines whether tirzepatide is medically appropriate for your situation. They will explain dosing, expected side effects, and what the treatment timeline looks like.

If the provider determines you are a good candidate, they write a prescription that is sent to a licensed compounding pharmacy. The pharmacy prepares your medication and ships it to your home, usually within a few business days.

One thing worth verifying: ask about the pharmacy’s credentials. A trustworthy provider will work with pharmacies that can provide a Certificate of Analysis for each batch, confirming the potency and purity of the medication you are receiving.

What to Expect Once You Start

Tirzepatide is administered as a subcutaneous injection once per week. The dosing follows a titration schedule, typically starting at 2.5 mg and increasing gradually every four weeks depending on your tolerance and response. Most providers will walk you through the injection process and provide clear instructions, so even if you have never self-injected before, it is manageable.

The most common side effects are gastrointestinal: nausea, diarrhea, constipation, and reduced appetite. These tend to be most noticeable during the first few weeks at each new dose level and usually improve as your body adjusts. If side effects become difficult to manage, your provider can slow the titration or adjust your protocol. You should not try to manage this on your own.

Many patients notice a meaningful reduction in appetite within the first week or two. 

Significant weight loss usually becomes visible between weeks four and eight, with continued progress over several months. Individual timelines vary, and patience matters here. This is not a medication that delivers overnight results, but the clinical data supports substantial long-term outcomes for patients who stay on protocol.

Red Flags to Watch For

The surge in demand for tirzepatide has attracted bad actors. Protect yourself by watching for a few warning signs.

Avoid any service that offers tirzepatide without requiring a medical evaluation. This is a prescription medication, and there is no legal way to obtain it without a provider reviewing your health history. 

Be skeptical of platforms selling “oral tirzepatide” tablets or drops. As of 2026, there is no FDA-approved oral formulation of tirzepatide, and anything marketed as such should be treated with extreme caution.

Also watch out for pricing that seems dramatically lower than the market. Compounded tirzepatide has real costs associated with pharmaceutical-grade ingredients, sterile compounding, and quality testing. If the price does not reflect that, something is being cut.

If you want to understand how your provider ensures medication quality, ask whether they work with FDA-registered compounding pharmacies and whether Certificates of Analysis are available for review.

Making an Informed Decision

The compounded tirzepatide situation is more nuanced than most internet articles suggest. It is not as simple as “order it online,” and it is not as scary as “it’s all being shut down.” The reality is somewhere in between, and it depends heavily on working with a knowledgeable, transparent provider who stays current with FDA guidance.

If you have been thinking about whether compounded tirzepatide is the right option for your weight loss goals, the best next step is a conversation with a licensed provider who can evaluate your specific situation. A telehealth consultation is designed to do exactly that: walk you through the process, answer your questions, and determine whether this medication fits your health profile. No pressure, no obligation. Just an honest clinical conversation about what makes sense for you.

The availability and legal status of compounded tirzepatide is subject to FDA regulation and may change. This article reflects information available at the time of publication. Always consult a licensed provider.

If you have been researching weight loss medications, chances are semaglutide has come up more than once. And with good reason. The STEP 1 trial published in the New England Journal of Medicine found that participants taking semaglutide 2.4 mg lost an average of about 15% of their body weight over 68 weeks, which is a substantial result for a non-surgical treatment. But here is the part that trips a lot of people up: actually getting a prescription.

There is no shortage of confusing (and sometimes sketchy) information online about how to get semaglutide. Some sites make it sound like you can order it the way you would a supplement. Others bury the process in so much medical jargon that it feels impossible to figure out.

So let’s clear it up. Semaglutide is a prescription medication. It is only available through a licensed healthcare provider following a medical evaluation. 

There are no legal shortcuts around that, and honestly, you would not want there to be. This is a medication that affects your metabolic system, and having a provider oversee your treatment is what makes it safe. 

That said, if you meet the medical criteria, the process is more straightforward than it might seem. Here is how the process actually works, step by step.

Understanding What Semaglutide Is (and Is Not)

Before we walk through the prescription process, it helps to understand what you are asking for. Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. It mimics a hormone your body naturally produces after eating, which helps regulate appetite and blood sugar levels.

You may have heard of brand names like Ozempic (approved for type 2 diabetes) or Wegovy (approved specifically for chronic weight management). There are also compounded versions of semaglutide produced by FDA-registered compounding pharmacies, which offer an alternative for patients who may not have access to or cannot afford the brand-name versions.

What semaglutide is not: a quick fix, a supplement, or something you should buy from an unregulated online source. If someone is selling it without requiring a medical evaluation, walk away.

Step 1: Decide Between In-Person and Telehealth

The first decision you will make is how you want to see a provider. You have two main options.

An in-person visit with your primary care doctor, endocrinologist, or a weight management specialist is one route. If you already have a provider who knows your medical history, this can be a natural starting point. The downside is that scheduling can take weeks, and not every provider is comfortable prescribing GLP-1 medications for weight loss.

Telehealth is the other option, and it has become increasingly popular for this exact reason. A telehealth consultation allows you to meet with a licensed provider from home, often with significantly shorter wait times. The medical evaluation is the same. The provider reviews your health history, discusses your goals, assesses whether semaglutide is appropriate for your situation, and writes a prescription if it is medically justified.

Many patients prefer telehealth because it removes the logistical barriers. No driving to an office, no sitting in a waiting room, no taking half a day off work. The medical rigor stays the same, but the convenience factor is real.

Step 2: Complete a Medical Intake Form

Whether you go in person or through telehealth, the process starts with a medical intake. This is where the provider gathers the information they need to determine whether semaglutide is right for you.

Expect questions about your current weight and BMI, your medical history (including any history of thyroid issues, pancreatitis, or kidney problems), medications you are currently taking, previous weight loss attempts, and your overall health goals.

For telehealth platforms, this intake is typically an online form that takes just a few minutes to complete. Be thorough and honest. The more accurate your information, the better your provider can evaluate your candidacy and build a safe treatment plan.

If you are curious about what a prescribing and safety evaluation looks like in practice, it is worth understanding the clinical criteria providers use before writing a prescription.

Step 3: Meet With a Licensed Provider

This is the core of the process. A licensed healthcare provider will review your intake information and, in most telehealth models, conduct a consultation with you directly. This is not a rubber stamp. Providers are evaluating real clinical criteria.

Generally, semaglutide for weight management is considered appropriate for adults with a BMI of 30 or higher (obesity), or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol.

During your consultation, a good provider will explain how semaglutide works, what side effects to expect (nausea is common early on, especially during dose increases), what the dosing schedule looks like, and how long treatment typically lasts. They should also ask about your diet, activity level, and what support you might need beyond the medication itself.

If semaglutide is not the right fit, a responsible provider will tell you that. Not everyone is a candidate, and that is okay. There are other treatment options worth exploring depending on your specific health profile.

Step 4: Get Your Prescription Filled

Once your provider determines that semaglutide is appropriate for you, they will write a prescription. Where it gets filled depends on the type of semaglutide prescribed.

Brand-name versions like Wegovy or Ozempic go through a traditional pharmacy, and insurance coverage varies widely. Some plans cover it, many do not, and prior authorization requirements can add delays.

Compounded semaglutide is prepared by FDA-registered compounding pharmacies or state-licensed 503A pharmacies. These formulations are not FDA-approved products in the brand-name sense, but they are produced under strict regulatory oversight. Many telehealth providers work with specific pharmacies and can coordinate shipping directly to your door, typically within 3 to 5 business days.

Either way, you should receive clear instructions on dosing, injection technique (semaglutide is administered as a subcutaneous injection, usually once weekly), and storage requirements.

Step 5: Start Treatment and Stay Connected to Your Provider

Getting the prescription is not the finish line. It is actually just the beginning.

Semaglutide treatment follows a titration schedule, meaning you start at a low dose and gradually increase over several weeks. This approach helps minimize side effects and gives your body time to adjust. Most patients begin at 0.25 mg per week and work their way up to a therapeutic dose over the course of a few months.

During this time, staying in contact with your prescribing provider matters. They can help you manage side effects, adjust your dose if needed, and make sure the medication is doing what it should be doing. Good telehealth platforms make this easy with follow-up visits and secure messaging so you are never guessing about your treatment.

This is also the phase where nutrition and movement start to play a bigger role. Semaglutide reduces appetite, which creates an opportunity to build healthier eating habits. But the medication works best when it is part of a broader plan, not a standalone solution. Your provider can help connect you with resources or guidance on how to make the most of your treatment window.

What to Watch Out For

Not every provider or platform offering semaglutide is operating responsibly. Here are a few red flags to keep in mind.

Be cautious if a service promises semaglutide without a medical evaluation. That is not how prescription medication works, and any provider skipping that step is cutting corners on your safety. Similarly, be wary of prices that seem too good to be true, providers who are difficult to reach after you have paid, or platforms that cannot tell you where their medication is compounded.

A reputable provider will be transparent about their process, their pharmacy partners, and the clinical criteria they use. They should also be easy to reach with questions, because you will have them, especially in the first few weeks.

If you want to verify the quality and purity of a compounded medication, look for a Certificate of Analysis (CofA). Reputable providers make these available for review so patients know exactly what they are receiving.

The Bottom Line

Getting semaglutide legally and safely is not complicated, but it does require a real medical evaluation by a licensed provider. That is not a barrier. It is a safeguard. Whether you go through your primary care doctor or a telehealth platform, the steps are straightforward: complete an intake, consult with a provider, get a prescription if appropriate, and stay connected to your care team throughout treatment.

Our intake form takes just a few minutes, and a licensed provider typically reviews cases within 24 hours. If you have been thinking about whether semaglutide might be right for you, starting the process is easier than you might expect, and there is absolutely no judgment involved. It is just a conversation about your health.

If you have questions or want to learn more about whether semaglutide may be appropriate for you, our team is here to help. You can reach out at any time, and we will guide you through the next steps with clear, straightforward information. 

Semaglutide is a prescription medication. It is only available through a licensed healthcare provider following a medical evaluation. This article is for informational purposes only and does not constitute medical advice.

Peptide therapy has shifted from a niche tool to a key element of personalized medicine. In recent years, patients sought peptides for healing, metabolism, and recovery. Regulatory changes in 2023 limited access, prompting some patients to turn to unregulated online sources and creating confusion.

With new guidance from the U.S. Department of Health and Human Services (HHS), about 14 previously restricted peptides are expected to regain legal, prescribable status through licensed compounding pharmacies. This change marks a key moment for patient safety, clinical oversight, and regenerative medicine.

To help patients and clinicians adapt, let’s break down what this regulatory change means, why pharmaceutical-grade peptides matter more than ever, and how to safely navigate peptide therapy in 2026 and beyond.

Why This Regulatory Shift Matters

The re-legalization of these peptides is more than a policy update — it is a restoration of safe access. When the 2023 restrictions removed many peptides from clinical use, patients were left with two options: discontinue therapy or turn to unregulated “research-use-only” peptides sold online. Many chose the latter, often without understanding the risks.

The updated HHS position allows clinicians to prescribe peptides from FDA-inspected, cGMP-compliant compounding pharmacies, ensuring that the products meet strict safety and quality standards.

This shift supports:

• Safer access to medically supervised peptide therapy
• Better treatment outcomes through individualized dosing and monitoring
• Reduced reliance on black-market peptides
• Improved patient education and clinical oversight

For patients seeking to optimize their health, understanding these changes is crucial to accessing safer, more effective care moving forward.

Why Pharmaceutical-Grade Peptides Are Essential for Patient Safety

Not all peptides are created equal. The difference between pharmaceutical-grade peptides and online “research peptides” is dramatic—and directly affects patient safety.

Pharmaceutical-grade peptides are:

• Produced in FDA-inspected, cGMP-certified facilities
• Tested for purity, potency, sterility, and endotoxin levels
• Manufactured with validated processes and strict quality control
• Stored and shipped under temperature-controlled conditions
• Prescribed by clinicians who monitor dosing, labs, and safety

Research-use-only peptides are:

• Sold online with labels such as “not for human consumption.”
• Manufactured without regulatory oversight
• Frequently contaminated or mislabeled.
• Inconsistent in potency or molecular structure
• Not tested for sterility or safety
• Not legally approved for medical use

Why this matters for patients

Peptides are biologically active compounds, meaning they have effects in the body, and they interact with hormonal (hormone-related), metabolic (body process–related), and immune (defense system–related) pathways. When purity or potency (strength) is inconsistent, patients may experience:

• Ineffective treatment
• Unexpected side effects
• Immune reactions
• Contamination-related complications
• Hormonal dysregulation

Pharmaceutical-grade peptides minimize these risks by ensuring products meet label claims accurately.

The Difference Between Research Peptides and Clinically Supervised Therapy

Many patients underestimate the key differences between these categories. The issue is not just purchase location — it’s also legality, safety, and oversight.

Research Peptides

These products are marketed for laboratory use only. They are not intended for human consumption and are not regulated for safety. Patients who purchase these products online are essentially self-experimenting without medical supervision.

Clinically Supervised Pharmaceutical-Grade Peptide Therapy

This model ensures:

• A licensed clinician evaluates the patient.
• A legitimate diagnosis and treatment plan are established.
• Dosing is individualized
• Labs are monitored
• Side effects are tracked.
• Therapy is adjusted based on clinical response.

This is the only legal and safe approach for health-focused peptide use.

Why Quality, Sourcing, and Clinical Oversight Matter More Than Ever

As peptides like Tesamorelin, Ipamorelin, and BPC-157 regain clinical use, proper sourcing and medical supervision are increasingly important.

Tesamorelin

A type of medication known as a growth hormone–releasing hormone (GHRH) analog, which helps support metabolism and reduce visceral fat (fat around organs).

Why oversight matters: Tesamorelin affects IGF-1 pathways, requiring lab monitoring to ensure safe dosing and avoid hormonal imbalance.

Ipamorelin

A peptide (small protein) that gently stimulates growth hormone release, used for recovery, improving sleep quality, and supporting healthy body composition (proportion of fat, muscle, etc.).

Why oversight matters: When combined with other GH-modulating therapies, dosing must be carefully managed to avoid overstimulation.

BPC-157

A peptide known for supporting tissue repair, gut lining integrity, and recovery.

Why oversight matters: Online versions of BPC-157, a peptide for tissue and gut health, are notoriously inconsistent. Studies show contamination and incorrect amino acid sequences (errors in the building blocks that make proteins) in many research-grade products.

Clinical oversight ensures:

• Correct dosing
• Appropriate timing and cycling
• Monitoring of IGF-1, metabolic markers, and inflammatory markers
• Avoidance of drug interactions
• Adjustment based on patient response
• Early detection of side effects

Peptides are powerful tools — but like any therapy, they require expertise to use safely and effectively.

What Patients Can Expect as Peptides Become Legal Again

With the return of these peptides to clinical practice, patients will benefit from:

1. Safer Access

No more guessing about purity or potency. Pharmaceutical-grade peptides are produced by regulated compounding pharmacies that meet rigorous quality standards.

2. Personalized Treatment Plans

Clinicians can tailor therapy based on:

• Health goals
• Lab results
• Medical history
• Response to treatment

3. Better Outcomes

When peptides are dosed correctly and monitored clinically, patients typically experience:

• Improved recovery
• Enhanced metabolic function
• Better sleep
• Stronger immune resilience
• More predictable results

4. Reduced Risk

Clinical oversight dramatically reduces the likelihood of:

• Contamination
• Incorrect dosing
• Hormonal imbalance
• Adverse reactions

How Patients Can Stay Safe Moving Forward

As peptides re-enter the clinical landscape, patients should follow these safety principles:

• Use only pharmaceutical-grade peptides from licensed compounding pharmacies.
• Avoid all online “research peptides” — regardless of branding or marketing.
• Work with a trained clinician experienced in peptide therapy.
• Monitor biomarkers, including IGF-1, metabolic markers, and inflammatory markers.
• Report any side effects promptly.
• Follow dosing and cycling protocols exactly as prescribed.

Peptide therapy works best and safest with medical supervision.

Conclusion

The reinstatement of approximately 14 peptides to legal clinical use marks a pivotal moment for regenerative and functional medicine, offering patients renewed access to regulated, pharmaceutical-grade therapies under clinical supervision. This change supports enhanced safety, more reliable outcomes, and a sensible, science-driven approach to health optimization.

As peptides such as Tesamorelin, Ipamorelin, and BPC-157 return, focus on clinical oversight and sourcing. Used properly, they can enable healing and wellness safely under the supervision of trained clinicians.

Precision Telemed Puts Patient Safety First

When it comes to peptide therapy, safety is not optional — it is our standard:

• Clinician oversight: Every peptide therapy is prescribed by a licensed medical professional following a patient-provider consultation.
• Trusted pharmacy partnerships: Peptides are compounded in U.S.-based 503A/503B pharmacies with rigorous quality checks.
• Verified medication quality: Every prescription includes a Certificate of Analysis (CoA) confirming potency, purity, and consistency.
• Ongoing support: Our programs offer scientific review, clinical monitoring, and patient guidance, preventing self-experimentation with unsafe products.

This approach ensures patients benefit from therapy safely and effectively, rather than risking exposure to unregulated research chemicals.

At Precision Telemed, every peptide therapy begins with a licensed clinician consultation and is fulfilled through verified, pharmaceutical-grade compounding pharmacies. If you are interested in learning whether peptide therapy may be appropriate for your health goals, schedule a consultation with our clinical team today.

APA References 

• Food and Drug Administration. (2023). Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov
• Health and Human Services. (2026). Statement from HHS Secretary Robert F. Kennedy Jr. on peptide compounding policy update. U.S. Department of Health and Human Services.
• International Peptide Society. (2024). Peptide therapy safety and clinical guidelines. https://peptidesociety.org
• U.S. Pharmacopeia. (2022). USP standards for compounded sterile preparations. https://www.usp.org
• World Health Organization. (2021). Quality assurance of pharmaceuticals: Good manufacturing practices and inspection. https://www.who.int

GLP-1 medications like semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) have transformed medical weight loss. Many patients experience meaningful, sustained fat loss, often for the first time. But as the scale drops, a common concern is how much muscle/lean mass is being lost as well.

In general, weight loss, especially rapid or significant weight loss, almost always includes some loss of lean mass, which includes muscle, water, organs, and connective tissue. Clinical trials of GLP-1 medications confirm that while on GLP-1 therapy most weight loss is fat, but lean mass can be a large portion of the loss because of how rapidly patients shed the pounds.

Why muscle loss can happen on GLP-1s

GLP-1s suppress appetite and often slow gastric emptying, particularly early in treatment. Many patients eat far fewer calories than before, sometimes unintentionally. When calorie intake drops quickly, the body pulls energy from both fat and lean tissue. As total caloric intake falls, protein intake often falls as well. Smaller meals, food aversions, and early satiety can lead to lower protein intake unless patients are intentional. Insufficient protein during weight loss increases the risk of losing lean mass rather than fat alone.

Another contributing factor is reduced mechanical demand. As body weight decreases, muscles are under less load in daily life. Without resistance training, the body may interpret this as a signal that less muscle is required. This pattern is not unique to GLP-1s and is seen across many forms of weight loss.

As awareness of this issue grows, patients and clinicians are exploring strategies to preserve muscle while continuing the metabolic benefits of GLP-1 therapy. One therapy that often enters the conversation is Sermorelin.

What is Sermorelin?

Sermorelin is a synthetic peptide that mimics growth hormone–releasing hormone (GHRH), a signal produced by the brain that stimulates the pituitary gland to release growth hormone (GH). Rather than supplying growth hormone directly, sermorelin works upstream in the GH axis: Sermorelin → pituitary GH release → increased IGF-1 signaling.

Growth hormone and insulin-like growth factor-1 (IGF-1) influence tissue repair,  metabolism, and body composition by stimulating fat breakdown (lipolysis) and decreasing fat storage (lipogenesis) in fat cells (adipocytes) and body. GH secretion naturally declines with age, obesity, and poor sleep, factors common in patients seeking GLP-1 therapy.

Potential benefits of Sermorelin during GLP-1 weight loss

1. Supporting muscle quality, not just size

Muscle health isn’t only about how much muscle you have—it also includes strength, recovery, mitochondrial function, and neuromuscular coordination.

Growth hormone plays a role in muscle protein turnover and repair, particularly when combined with resistance training. In studies of GHRH analogs in adults, activation of the GH axis was associated with increases in lean body mass.

Sermorelin may help preserve muscle quality and functional strength, even if some lean mass loss still occurs during weight reduction. Importantly, GH does not directly build muscle like anabolic steroids. Instead, it may create a more supportive internal environment for muscle maintenance when proper nutrition and training are present.

2. Improved recovery capacity during weight loss

GLP-1–associated weight loss can feel physically demanding; lower energy intake, reduced training tolerance, and fatigue during dose escalation are common.

Growth hormone plays a role in tissue repair and recovery, including connective tissue remodeling. Some patients report improved recovery and exercise tolerance with GH-axis stimulation, which could help maintain muscle by allowing more consistent resistance training.

3. Indirect benefits through sleep quality

A major daily pulse of growth hormone occurs shortly after sleep onset and is closely linked to slow-wave (deep) sleep. Poor sleep impairs muscle recovery, worsens insulin sensitivity, and increases fatigue.

Sermorelin is often reported to improve sleep continuity or depth. Better sleep could indirectly support muscle recovery, training adherence, and overall metabolic health. Any muscle-preserving strategy that improves sleep deserves consideration, even if the effect is indirect.

4. Favoring fat loss over lean loss (nutrient partitioning)

Growth hormone has known effects on lipolysis (fat breakdown) and free-fatty-acid mobilization. GH-axis stimulation shifts weight loss toward fat mass rather than lean mass.

This concept, known as nutrient partitioning, is one reason pharmaceutical companies are actively developing muscle-preserving agents to pair with GLP-1 therapies. While sermorelin is not one of these new investigational drugs, the theory aligns with why this combination is being explored.

5. Age-related considerations

GH secretion declines naturally with age. Patients over 40, postmenopausal women, and individuals with long-standing obesity may begin GLP-1 therapy with lower baseline GH output.

Sermorelin could partially offset this decline, potentially narrowing the gap in muscle-preservation outcomes between younger and older patients during weight loss. This does not mean Sermorelin “reverses aging,” but it may address a specific physiologic limitation.

Here’s the most important takeaway:

There is no direct clinical trial proving that Sermorelin prevents muscle loss specifically in patients using GLP-1 medications.

What we do have includes:

• robust data showing GLP-1s reduce lean mass alongside fat loss
• studies showing GH-axis stimulation with peptides like Sermorelin can influence body composition (increased lean mass and increased lipolysis)
• growing industry focus on muscle preservation as a recognized unmet need

Risks and limitations to understand

Sermorelin does not replace protein intake or resistance training.

GH-axis stimulation can cause side effects such as fluid retention, joint discomfort, tingling or numbness, headaches, and changes in glucose handling. IGF-1 levels should be monitored, more is not always better. Quality and sourcing matter significantly, and medical supervision is essential.

What matters for preserving muscle on GLP-1s

Whether or not Sermorelin is used, the most effective muscle-preserving tools remain:

• Resistance training (2–4 times per week)
• Intentional protein intake
  • A practical way many clinicians guide patients is to think in terms of up to 1 gram of protein per pound of goal body weight per day. This is not a requirement, and most patients will not consistently reach this number. However, using this target as a mental framework often results in patients consuming enough protein to support muscle preservation, even when actual intake falls well below 1 g/lb.
• Tracking strength and function, not just scale weight.

Sermorelin and GLP-1s bottom line

Sermorelin is discussed for muscle preservation on GLP-1s. For patients who are strength-training, prioritize protein, and work with knowledgeable clinicians, it is a reasonable adjunct to explore. But remember, the foundation remains unchanged: Muscle is preserved by use, fuel, and recovery, not by peptides alone.

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. Link: https://pubmed.ncbi.nlm.nih.gov/33567185/
2. Wilding JPH, et al. Impact of Semaglutide on Body Composition: STEP-1 Exploratory DXA Analysis. 2021. Link: https://pubmed.ncbi.nlm.nih.gov/33567185/
3. Look M, et al. Body Composition Changes with Tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025. Link: https://pubmed.ncbi.nlm.nih.gov/39996356/
4. Khorram O, et al. Long-Term GHRH Analog Administration in Older Adults. J Clin Endocrinol Metab. 1997. Link: https://pubmed.ncbi.nlm.nih.gov/9141536/
5. Walker RF, et al. Sermorelin as an Alternative to GH Therapy. 2006. Link: https://pubmed.ncbi.nlm.nih.gov/18046908/
6. Reuters. Regeneron reports muscle-preserving effects with experimental obesity drug. 2025. Link: https://www.reuters.com/business/healthcare-pharmaceuticals/regenerons-weight-loss-drug-helps-preserve-muscle-mass-study-2025-06-02/

Precision Telemed Clickable Links
Compounded Tirzepatide
Compounded Semaglutide
Sermorelin Peptide
NAD+ Injections
Testosterone Replacement Therapy
Hair Loss
Erectile Dysfunction

Feeling Drained During Your GLP-1 Weight-Loss Journey? Here’s How NAD⁺ Injections Might Help You Feel Like Yourself Again

Many patients start GLP-1 medications with clear goals. Better health, steady weight loss, and renewed confidence. Then, a few weeks in, they notice something they didn’t expect: exhaustion. Patients notice that they are finally losing weight but they feel like they’re “running on empty.”

That kind of fatigue is more common than most people think. As clinicians, we’ve seen it time and again, especially during the first few months on GLP-1 medications, such as semaglutide or tirzepatide. That being said, there are ways to support energy without derailing progress. One promising tool is NAD⁺ (nicotinamide adenine dinucleotide), a coenzyme essential for cellular energy production.

Let’s dive in to why fatigue can creep in during GLP-1 therapy, what NAD⁺ actually does inside your cells, and why NAD⁺ injections are gaining attention among people who want to feel energized again.

Why Fatigue Happens with GLP-1 Weight-Loss Therapy

GLP-1 receptor agonists work by slowing digestion and decreasing appetite, so you naturally eat less (Wilding et al. 989). When calorie intake drops, your body has to adapt; essentially, it starts running on stored energy instead of constant fuel. This metabolic shift is healthy, but it can make you feel sluggish, foggy, or mentally flat for a while.

We also see a few other contributors:

• Reduced calories and protein: muscles can temporarily lose fuel.
• Mild dehydration: appetite changes often mean lower fluid intake.
• Micronutrient shifts: your body is burning through reserves.
• Mitochondrial slowdown: the “power plants” in your cells produce less ATP when nutrients drop (Yoshino et al. 1225).

That last point is where NAD⁺ becomes especially interesting.

Meet NAD⁺: Your Cells’ Energy Middleman

Inside every cell, NAD⁺ helps turn food into ATP, the molecule that literally powers movement, focus, and repair (Bogan and Brenner 118). Think of it as a universal battery connector. Without enough NAD⁺, the entire energy chain sputters.

Levels of NAD⁺ naturally decline with age and stress (Verdin 1210). Rapid weight loss, reduced caloric intake, and hormonal changes can accelerate that dip. When NAD⁺ drops, so does mitochondrial performance, leaving you with slower metabolism, mental fog, and that mid-day crash we hear about so often.

Supporting NAD⁺ levels is about more than “feeling awake.” It’s about helping your cells produce energy efficiently again, so your weight-loss plan feels sustainable instead of draining.

How NAD⁺ Injections Work

NAD⁺ occurs naturally in the body, but oral supplements can be tricky, much of it breaks down in the gut before it ever reaches the bloodstream. Injectable NAD⁺, on the other hand, delivers it directly for faster and more complete absorption (Trammell et al. 12948).

It isn’t a caffeine rush or a stimulant hit. Patients describe it more like having their “battery” quietly recharged, a steadier kind of energy that builds over several days.

Reported benefits include:

• More consistent daytime energy
• Sharper concentration and mental clarity
• Easier post-workout recovery
• Less of the “afternoon crash” feeling

The mechanism makes sense: improving mitochondrial function through NAD⁺ replenishment allows every cell, from brain to muscle, to do its job more efficiently (Stein and Imai 1813).

What the NAD+ Research Tells Us

Scientific studies show that boosting NAD⁺; either through precursors such as nicotinamide riboside or via direct supplementation; can improve mitochondrial health, reduce oxidative stress, and support metabolic balance (Cantó et al. 840; Gomes et al. 1626).

In one study, NAD⁺ precursors increased muscle insulin sensitivity in prediabetic women (Yoshino et al. 1228). Others found improved cellular resilience and better energy metabolism during caloric restriction (Rajman et al. 505). There aren’t yet large trials on GLP-1 users specifically, but the biology lines up. Restoring NAD⁺ gives the body more of what it needs to adapt to weight loss gracefully. It’s a complementary therapy, not a replacement; GLP-1 targets appetite and insulin regulation, NAD⁺ supports the energy systems behind them.

Why So Many Patients Ask About NAD+

Typically, patients on GLP-1s often say, “I finally have control over my hunger, but I miss my old energy.” That’s where NAD⁺ can help bridge the gap. It supports sustainable vitality without relying on stimulants or sugar.

Unlike quick-fix solutions, NAD⁺ injections work at the cellular level. They don’t just mask fatigue; they help your body restore its natural rhythm (Rajman et al. 508). For anyone balancing work, family, and weight-loss goals, that steadier kind of energy can make all the difference.

What to Expect from NAD+ Therapy

Treatment plans vary, but most patients start with a series of injections administered by a licensed provider. Each session usually takes less than an hour. Energy improvements tend to appear gradually over several sessions as NAD⁺ levels stabilize.

Some describe it as “having my spark back.” Others simply notice fewer dips in focus or mood. If you’re using GLP-1 medication, your clinician will tailor dosing to complement your therapy and avoid overlap with other metabolic agents.

Who Might Benefit Most

NAD⁺ therapy may be particularly helpful for:

• Patients using GLP-1s who experience persistent fatigue
• Individuals adjusting to lower calorie intake
• Those maintaining weight loss and looking for better recovery
• Anyone under physical or cognitive stress

It’s not about perfection; it’s about feeling capable and balanced while your body transforms.

A Science-Backed Way to Support Your Energy

Weight-loss success should feel empowering, not exhausting. If you’ve been feeling drained on a GLP-1, ask your Precision Telemed provider whether NAD⁺ injections could fit into your care plan.

Our team focuses on evidence-based, patient-centered therapies that help you achieve lasting results, and feel your best while doing it. You’ve done the hard part by starting; NAD⁺ might just help you finish strong.

References

Bogan, K. L., and C. Brenner. “Nicotinic Acid, Nicotinamide, and Nicotinamide Riboside: A Molecular Evaluation of NAD⁺ Precursor Vitamins in Human Nutrition.” Annual Review of Nutrition, vol. 28, 2008, pp. 115–130. Link: Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition – PubMed

Cantó, C., et al. “The NAD⁺ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity.” Cell Metabolism, vol. 15, no. 6, 2012, pp. 838–847. Link: https://pubmed.ncbi.nlm.nih.gov/22682224/

Gomes, A. P., et al. “Declining NAD⁺ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging.” Cell, vol. 155, no. 7, 2013, pp. 1624–1638.
Rajman, L., et al. “NAD⁺ as a Metabolic Link between DNA Damage, Aging, and Disease.” Cell Metabolism, vol. 27, no. 3, 2018, pp. 502–514. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC4076149/

Stein, L. R., and S. Imai. “Specific Ablation of Nampt in Adult Neural Stem Cells Recapitulates the Age-Associated Decline in Neural Stem Cell Function.” Genes & Development, vol. 28, 2014, pp. 1812–1823. Link: https://pubmed.ncbi.nlm.nih.gov/24811750/

Trammell, S. A. J., et al. “Nicotinamide Riboside Is Uniquely and Orally Bioavailable in Mice and Humans.” Nature Communications, vol. 7, 2016, Article 12948. Link: https://www.nature.com/articles/ncomms12948

Verdin, E. “NAD⁺ in Aging, Metabolism, and Neurodegeneration.” Science, vol. 350, no. 6265, 2015, pp. 1208–1213. Link: https://pubmed.ncbi.nlm.nih.gov/26785480/

Wilding, J. P. H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, vol. 384, 2021, pp. 989–1002. Link: https://pubmed.ncbi.nlm.nih.gov/33567185/

Yoshino, J., et al. “Nicotinamide Mononucleotide Increases Muscle Insulin Sensitivity in Prediabetic Women.” Science, vol. 372, 2021, pp. 1224–1229. Link: https://pubmed.ncbi.nlm.nih.gov/33888596/

Yoshino, J., et al. “SIRT1 Activation Mediates the Beneficial Effects of Resveratrol on Mitochondrial Function.” Cell Metabolism, vol. 14, no. 5, 2011, pp. 612–620. Link: https://pubmed.ncbi.nlm.nih.gov/22560220/

Precision Telemed Clickable Links
Compounded Tirzepatide
Compounded Semaglutide
Sermorelin Peptide
NAD+ Injections
Testosterone Replacement Therapy
Hair Loss
Erectile Dysfunction

What is PCOS?

Polycystic ovarian syndrome (PCOS) is a common hormonal disorder that affects around 10–15% of women of reproductive age worldwide. Irregular menstrual cycles, signs of excess androgen hormones, including acne and hirsutism, insulin resistance, obesity, and infertility, frequently occur as a result of this condition. It has become more common for women to turn to Tirzepatide for PCOS.

Weight Loss is the Primary Management Goal in PCOS

The primary intervention is weight loss for most patients with PCOS, as weight loss can restore ovulatory cycles and improve metabolic abnormalities that pose health risks to women with PCOS. 

Although weight loss in patients who maintain long-term lifestyle changes, such as caloric restriction and exercise, can resolve ovulatory cycles and correct metabolic imbalances, it is difficult for many women to sustain long-term change through lifestyle modification alone, and the weight loss tends to return after a year or less. 

Other treatments currently used to manage PCOS aim to correct specific abnormalities. Goals of management include:

• Correction of metabolic abnormalities, which increase the risk of type 2 diabetes and cardiovascular disease.
• Management of symptoms of excess androgens: acne, excess hair growth, loss of scalp hair  
• Preventing hyperplasia of the uterine lining, which can lead to uterine cancer
• Contraception for women who do not wish to become pregnant, as irregular cycles can result in unintended pregnancy. 
• Ovulation induction for women who desire pregnancy.

Current Treatments for PCOS

• Combined oral contraceptives are the current mainstay of treatment.
  • Although these medications carry an increased risk of venous thromboembolic disease (pulmonary emboli, deep vein thrombosis) in women who have PCOS, it is similar to the risk in women without PCOS.
  • Alternative options such as progestin-only mini-pills or progestin-releasing IUDs reduce the risk of hyperplasia of the uterine lining, a risk factor for endometrial cancer, and provide a contraceptive alternative.
• Cosmetic treatments or direct hair removal are usually recommended initially for women with hirsutism caused by excess androgen hormones.
  • Antiandrogenic medications may be prescribed after 6 months of combined oral contraceptive therapy fails to achieve an adequate response to androgenic features.
• Metformin or other antidiabetic medications are prescribed for insulin resistance

 or type 2 diabetes.

• Metformin was once believed to improve hirsuitism in PCOS, but is less effective than treatment with combined oral contraceptives or anti-androgens. 
• Statin medications are prescribed for related lipid disorders, in addition to the usual lifestyle and dietary changes.

Weight Loss is a Key Component of the Treatment of PCOS

Most experts suggest that weight loss through lifestyle changes like diet and exercise should begin before women with PCOS start treatment to induce regular ovulation with combined oral contraceptives and antiandrogenic therapies. 

Women with PCOS, like women without PCOS, have been found to have variable responses to lifestyle changes like diet and exercise. More than a third of women with PCOS  in a small long-term study had a complete response after approximately 20 months of following a 1200-1400 kcal/day diet for 6 months, followed by mild caloric restriction and increased physical activity. However, many studies have found that maintaining lifestyle changes and sustained weight loss is inconsistent, with most weight regained within a year.

Tirzepatide’s Potential Benefits for the Treatment of  PCOS

PCOS is closely linked to insulin resistance, even in women who are at a healthy weight. When insulin levels are excessively high, the ovaries create too much androgen. This can make ovulation erratic and cause unwanted symptoms like infertility, androgenic symptoms like acne, and excessive abnormal hair growth.

In the SURMOUNT-1 study, patients without diabetes lost 15% to 21% of their initial body weight, depending on the dose. These results are highly important because decreasing weight can usually help with ovulation and androgen symptoms in women with PCOS.

Prior studies utilizing GLP-1 receptor agonists (e.g., liraglutide and semaglutide) in women with PCOS have demonstrated benefits in weight control, insulin resistance, and waist circumference, as well as signs of improved ovulatory regularity. Tirzepatide may be significantly more effective due to its novel dual receptor mechanism of action.

Tirzepatide and PCOS: What Lies Ahead

Tirzepatide may help women with PCOS by: 

• Increasing insulin sensitivity and reducing insulin resistance are primary features of PCOS.

• Improving ovulatory regulation and fertility
  • Weight is the most important element affecting ovulatory cycles and fertility.
• Increasing and sustaining weight loss.
  • The SURMOUNT-4 study, a randomized clinical trial of continued maintenance of weight reduction in adults with obesity, treated participants with weekly doses of tirzepatide for 36 weeks. The mean weight reduction at 36 weeks was 20.9%, and participants were randomized to receive either a placebo or continued tirzepitide.
  • Participants who were randomized to tirzepatide instead of placebo from week 36 for a further 52 weeks were found to maintain at least 80% of their weight loss, compared to 16.6% of those who were randomized to the placebo.
• Hirsuitism and hyperandrogenism.
  • Lowering insulin levels may limit the production of ovarian androgens, which could make cycles more regular and possibly boost conception.
• Reducing metabolic and cardiovascular risk
  •  Women with PCOS are more prone to developing type 2 diabetes and heart disease. Tirzepatide’s effects may lessen these risks over time.

Additional research will answer these questions, as there is a good deal of interest in the potential of tirzepatide for the management of PCOS

References

Anala AD, Saifudeen ISH, Ibrahim M, Nanda M, Naaz N, Atkin SL. The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome. J Clin Med. 2023;12(14):4575. Published 2023 Jul 10. doi:10.3390/jcm1214457 Link: https://pubmed.ncbi.nlm.nih.gov/37510690/

Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945 Link: https://jamanetwork.com/journals/jama/fullarticle/2812936

Domecq JP, Prutsky G, Mullan RJ, et al. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98(12):4646-4654. doi:10.1210/jc.2013-2374 Link: https://pubmed.ncbi.nlm.nih.gov/24092830/

Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225. Published 2021 Nov 24. doi:10.1186/s12933-021-01412-5 Link: https://pubmed.ncbi.nlm.nih.gov/34819089/

Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown). 2008;9(10):987-992. doi:10.2459/JCM.0b013e32830b58d4 Link: https://pubmed.ncbi.nlm.nih.gov/18799960/

Hoeger KM. Obesity and lifestyle management in polycystic ovary syndrome. Clin Obstet Gynecol. 2007;50(1):277-294. doi:10.1097/GRF.0b013e31802f54c8 Link: https://pubmed.ncbi.nlm.nih.gov/17304042/

Moreira RO, Valerio CM, Hohl A, et al. Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Arch Endocrinol Metab. 2024;68:e240422. Published 2024 Nov 25. doi:10.20945/2359-4292-2024-0422 Link: https://pubmed.ncbi.nlm.nih.gov/39664998/

Norman RJ, Noakes M, Wu R, Davies MJ, Moran L, Wang JX. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update. 2004;10(3):267-280. doi:10.1093/humupd/dmh018 Link: https://pubmed.ncbi.nlm.nih.gov/15140873/

Pasquali R, Gambineri A, Cavazza C, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol. 2011;164(1):53-60. doi:10.1530/EJE-10-0692 Link: https://pubmed.ncbi.nlm.nih.gov/20956435/

Sassin MD, A. M., SangiHaghpeykar MD, PhD, H., Kjersti, S., Aagaard, PhD, M., & Detti MD, L. (2023, October). Effects of metformin alone versus metformin and tirzepatide on weight loss in patients with polycystic ovarian syndrome (PCOS) [Poster session]. POSTER ABSTRACT SESSION: REPRODUCTIVE MEDICINE- NON-INFERTILITY . Link: https://www.fertstert.org/article/S0015-0282(23)01397-3/fulltext

Skow MA, Bergmann NC, Knop FK. Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’. Diabetes Obes Metab. 2016;18(9):847-854. doi:10.1111/dom.12685 Link: https://pubmed.ncbi.nlm.nih.gov/27160961/

van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;20
15(4):CD010334. Published 2015 Apr 28. doi:10.1002/14651858.CD010334.pub2 Link: https://pubmed.ncbi.nlm.nih.gov/25918921/

Precision Telemed Clickable Links
Compounded Tirzepatide
Compounded Semaglutide
Sermorelin Peptide
NAD+ Injections
Testosterone Replacement Therapy
Hair Loss
Erectile Dysfunction